ReviewImmunological reviews2017
Immune recognition of irradiated cancer cells.
Review in Immunological reviews, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed.
- Screening and identification of key genes related to the immune microenvironment of rectal cancer influenced by radiotherapy based on bioinformatics methods.Discover oncology · 2026Article
- The efficacy of sequential radiotherapy after the combination of TACE with lenvatinib and anti-PD-1 antibodies for unresectable HCC.The oncologist · 2026Article
- New Approaches in Radiotherapy.Cancers · 2025Review
- Neoadjuvant chemoradiotherapy up-regulates PD-L1 in radioresistant colorectal cancer.Clinical and translational radiation oncology · 2025Article
- Kinetic Assessment of HMGB1 Exodus by Automated Live Cell Imaging.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Translational Frontiers and Clinical Opportunities of Immunologically Fitted Radiotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Review
- The impact of the senescent microenvironment on tumorigenesis: Insights for cancer therapy.Aging cell · 2024Review
- Combining theranostic/particle therapy with immunotherapy for the treatment of GU malignancies.BJUI compass · 2024Review
- Immunological signatures from irradiated cancer-associated fibroblasts.Frontiers in immunology · 2024Article
- Immune checkpoint inhibitor use in head and neck squamous cell carcinoma: the current landscape and future perspectives.Future oncology (London, England) · 2024Review
- Update on Radiotherapy Changes of Nasopharyngeal Carcinoma Tumor Microenvironment.World journal of oncology · 2023Review
- Review
- Low-Dose Non-Targeted Effects and Mitochondrial Control.International journal of molecular sciences · 2023Review
- Article
- Combined radiation- and immune checkpoint-inhibitor-induced pneumonitis - The challenge to predict and detect overlapping immune-related adverse effects from evolving laboratory biomarkers and clinical imaging.Neoplasia (New York, N.Y.) · 2023Article
- Article
- Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1.Oncoimmunology · 2023Article
- Case report: Interstitial implantation radiotherapy combined with immunotherapy and GM-CSF in oligometastatic platinum-resistant ovarian cancer.Frontiers in immunology · 2023Article
- Molecular mechanisms and therapeutic applications of huaier in breast cancer treatment.Frontiers in pharmacology · 2023Review
- Safety and feasibility of toripalimab plus lenvatinib with or without radiotherapy in advanced BTC.Frontiers in immunology · 2023Article
Corrections and comments
- Erratum issuedCorrigendum.2018
Authors and funding
6 authors.
Funding
Abstract
Ionizing irradiation has been extensively employed for the clinical management of solid tumors, with therapeutic or palliative intents, for decades. Until recently, radiation therapy (RT) was believed to mediate antineoplastic activity mostly (if not only) as a consequence of cancer cell-intrinsic effects. Indeed, the macromolecular damage imposed to malignant cells by RT initiates one or multiple signal transduction cascades that drive a permanent proliferative arrest (cellular senescence) or regulated cell death. Both these phenomena show a rather linear dose-response correlation. However, RT also mediates consistent immunological activity, not only as an "on-target effect" originating within irradiated cancer cells, but also as an "off-target effect" depending on the interaction between RT and stromal, endothelial, and immune components of the tumor microenvironment. Interestingly, the immunological activity of RT does not exhibit linear dose-response correlation. Here, we discuss the mechanisms whereby RT alters the capacity of the immune system to recognize and eliminate irradiated cancer cells, either as an "on-target" or as on "off-target" effect. In particular, we discuss the antagonism between the immunostimulatory and immunosuppressive effects of RT as we delineate combinatorial strategies to boost the former at the expenses of the latter.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.